Simvastatin Susp.

Phase 2Small molecule

FForbes Porter, M.D.

Simvastatin Susp. is one of 5 small molecule programs targeting Smith-Lemli-Opitz syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Smith-Lemli-Opitz SyndromeActive, not recruiting

Smith-Lemli-Opitz SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Smith-Lemli-Opitz Syndrome

#DrugCompanyPhaseTrials

Zocor

OOrganon and Co

Approved

—2

Antioxidants

IInstitute of Child Health

Phase 2

1 3

Cholbam

MMirum Pharmaceuticals, Inc.

Phase 2

1 4

Simvastatin Susp.

FForbes Porter, M.D.

Phase 2

1 5

Cholesterol

EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Smith-Lemli-Opitz syndrome1 trial

Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

Completed·FForbes Porter, M.D.·Phase 2·NCT00064792·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Simvastatin Susp.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Simvastatin Susp. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Simvastatin Susp.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forbes Porter, M.D. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FForbes Porter, M.D.

Simvastatin Susp.

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Smith-Lemli-Opitz syndrome1 trial

References

Drug Info

Quick Facts

Related News